Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipocalimab withdrawal study in adults with CIDP
2021-003234-37Phase 2Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nipocalimab in chronic inflammatory demyelinating polyneuropathy (CIDP) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Time to first relapse event. Started Mar 2022; status: active.
02
Drugs
nipocalimab
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on 2021-003234-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003234-37.